Storia in 5 fonti

Abivax share plunge may change deal outlook

The drugmaker has been viewed as a near-term takeover target for Big Pharma.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

axios.comStai leggendo4 h fa

Abivax share plunge may change deal outlook

The drugmaker has been viewed as a near-term takeover target for Big Pharma.

originale

cnbc.com12 h fa

Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update

Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.

Leggi questa versione → originale

biopharmadive.com19 h fa

AbiVax falls as safety worries cloud ‘landmark’ immune drug results

AbiVax obefazimod showed 39-40% Phase 3 remission—nearly double marketed IBD competitors (19-32%)—but cancer cases sent stock down 30%. FDA approval remains likely: Rinvoq precedent shows $8B+ sales persist despite boxed malignancy warnings.

Leggi questa versione → originale

zerohedge.com7 h fa

Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street

"The cancer signal complicates matters."

Leggi questa versione → originale

qz.com5 h fa

Abivax stock plunges on cancer signal in ulcerative colitis trial

Jefferies downgraded the French biotech to Hold and cut its price target nearly in half, warning the cancer overhang won't resolve quickly

Leggi questa versione → originale

Timeline cronologica

martedì 2 giugno 2026·biopharmadive.com
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
martedì 2 giugno 2026·cnbc.com
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
martedì 2 giugno 2026·zerohedge.com
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
"The cancer signal complicates matters."
martedì 2 giugno 2026·qz.com
Abivax stock plunges on cancer signal in ulcerative colitis trial
Jefferies downgraded the French biotech to Hold and cut its price target nearly in half, warning the cancer overhang won't resolve quickly
martedì 2 giugno 2026·axios.com
Abivax share plunge may change deal outlook
The drugmaker has been viewed as a near-term takeover target for Big Pharma.